GPCR Biology-Informed Drug Discovery in Asthma
1Department of Medicine, Pulmonary and Critical Care Medicine, Center for Translational Medicine, Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University, Philadelphia, PA 19107.
American Journal of Respiratory Cell and Molecular Biology
|August 14, 2026
Summary
New G protein-coupled receptor (GPCR) insights and technologies offer novel asthma treatment strategies beyond traditional methods. These advances in GPCR biology and drug discovery promise improved therapeutic validation and clinical development for asthma.
Area of Science:
- Pharmacology
- Molecular Biology
- Drug Discovery
Background:
- Traditional asthma therapies like beta-agonists and biologics have limitations.
- Recent discoveries include biased signaling, receptor dimerization, and signaling microdomains.
- These insights reveal new therapeutic targets for asthma.
Purpose of the Study:
- To review advances in GPCR biology and drug discovery for asthma.
- To highlight how new GPCR concepts inform discovery platforms.
- To discuss improved validation strategies for GPCR therapeutics.
Main Methods:
- Review of recent literature on GPCR biology and asthma therapeutics.
- Synthesis of information on structural biology, computational modeling, and machine learning applications.
- Discussion of biosensor-based pharmacology and physiologically relevant airway models.
Main Results:
- Emerging GPCR concepts provide new therapeutic opportunities.
- Targeting receptor and post-receptor signaling control points is feasible.
- Advanced validation methods enhance translational fidelity.
Conclusions:
- GPCR therapeutics can complement existing asthma biologic therapies.
- Innovations in GPCR targeting and validation are reshaping asthma drug development.
- Future clinical development may be significantly impacted by GPCR-targeted drugs.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:12GPCR Desensitization
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...